3

PRIMARY DOCUMENT

Company: IOVANCE BIOTHERAPEUTICS, INC.
Filed: October 20, 2017
Period of Report: October 20, 2017
Accession Number: 0001250853-17-000093

View Document ↗ View on SEC.gov ↗